Skip to main content

Table 1 Correlation of nucleus and cytoplasmic ERα and ERβ1 with clinicopathological parameters in ovarian cancer

From: Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis

Characteristics

Case (n)

Nucleus ERα

Cytoplasmic ERα

 

Nucleus ERβ1

 

Cytoplasmic ERβ1

 
  

Mean ± SD

p-value

Mean ± SD

p-value

 

Mean ± SD

p-value

 

Mean ± SD

p-value

 

Stage (FIGO)

 Early (I-II)

49

3.71 ± 3.32

  

1.00 ± 1.75

  

5.60 ± 1.94

  

3.65 ± 1.67

  

 Late (III-IV)

37

5.54 ± 3.12

0.012 *

0.22 ± 0.92

0.016 *

6.35 ± 1.64

0.052*

 

2.84 ± 1.39

0.101*

 

Histological grade

 Low (1–2)

56

4.11 ± 3.48

  

0.80 ± 1.62

  

6.25 ± 1.97

  

3.39 ± 1.67

  

 High (3)

33

4.85 ± 3.08

0.370*

 

0.36 ± 1.17

0.178*

 

5.42 ± 1.68

0.046 *

2.79 ± 1.43

0.046 *

Histology

 Serous

35

5.43 ± 3.15

  

0.34 ± 1.14

  

6.40 ± 1.94

  

2.91 ± 1.46

  

 Clear Cell

17

1.06 ± 2.02

  

0.71 ± 1.58

  

6.76 ± 1.64

  

3.06 ± 1.78

  

 Mucinous

9

2.22 ± 2.73

  

0.44 ± 1.33

  

5.56 ± 2.46

  

3.44 ± 2.40

  

 Endometrioid

29

5.90 ± 2.68

< 0.001

 

1.10 ± 1.82

0.230

 

5.20 ± 1.54

0.021

 

3.40 ± 1.35

0.567

 

 Serous/Clear Cell

52

4.00 ± 3.49

  

0.46 ± 1.29

  

6.52 ± 1.84

  

2.96 ± 1.56

  

 Mucinous/Endometrioid

38

5.05 ± 3.09

0.143*

 

0.95 ± 1.72

0.129*

 

5.28 ± 1.76

0.003 *

3.41 ± 1.62

0.157*

 

 Clear Cell

17

1.06 ± 2.02

  

0.71 ± 1.58

  

6.76 ± 1.64

  

3.06 ± 1.78

  

 Non-Clear Cell

73

5.23 ± 3.10

< 0.001 *

0.66 ± 1.49

0.905*

 

5.81 ± 1.92

0.053*

 

3.18 ± 1.56

0.593*

 

Chemosensitivitya

 Sensitive

63

4.64 ± 3.12

  

0.76 ± 1.58

  

6.12 ± 1.93

  

3.14 ± 1.70

  

 Resistant

13

4.38 ± 3.97

0.885*

 

0.31 ± 1.11

0.325*

 

5.85 ± 1.46

0.609*

 

2.77 ± 0.73

0.409*

 
  1. Those with significant P-values are underlined. ↑Increase expression. ↓Decrease expression
  2. *Mann–Whitney test; Kruskal–Wallis rank test
  3. aChemosensitive-patients remained disease free more than 6 months after completion of first-line chemotherapy
  4. Intensity values are expressed as “Histoscores” as specified in Methods